Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Lingtai Biopharmaceuticals

Request full access

Innovative drug discovery advancing precision protein degradation for autoimmunity and oncology

Huangpu, ChinaFounded 2019Biotech & Life Sciences

About Lingtai Biopharmaceuticals

Leadingtac is a biotechnology company focused on the discovery and development of innovative drugs, particularly in the field of targeted protein degradation (TPD). The company operates in the biopharmaceutical market, serving clients in the healthcare and pharmaceutical sectors. Leadingtac's business model revolves around developing novel drug candidates that address unmet medical needs in areas such as autoimmunity and oncology. The company generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other biotech and pharmaceutical companies. Leadingtac's management team comprises experienced professionals from Chinese, American, and European biotech and pharmaceutical industries, bringing a wealth of expertise to the company's operations. The company has been recognized for its innovation, being selected as one of KPMG China's 2nd Biotechnology Innovation 50 Companies. Leadingtac is currently advancing its first protein degrader toward clinical trial applications in China, the U.S., and Australia, with a focus on transforming patients' lives through precision medicine.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
23.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Precision Medicine, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Nov 2024 $14M $55M Tianrui Fengnian Investment · Zhang Ke Lingyi · Longpan Investment ↗
SEEDEquity / VC Nov 2021 $0 — Yuansheng BioVenture ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Lingtai Biopharmaceuticals website traffic

Latest recorded traffic for Lingtai Biopharmaceuticals is 150 monthly website visits, down 87.5% over the last three months.

Latest monthly visits150 3-month web change-87.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Lingtai Biopharmaceuticals in the Huangpu ecosystem

Live from Dealroom

The Lingtai Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Yuansheng BioVenture

Series A3 investors entered at this stage

  • Longpan Investment
  • Tianrui Fengnian Investment
  • Zhang Ke Lingyi
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Lingtai Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lingtai Biopharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.